BI/Lilly move to shore up Trajenta USP
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim and Eli Lilly are bolstering the position of their third-to-market dipeptidyl peptidase-4 (DPP-4) inhibitor drug linagliptin (Trajenta/Tradjenta) by initiating a new Phase III trial which, if successful, will emphasize the competitive advantage of linagliptin over rival drugs such as Merck & Co's Januvia (sitagliptin) and Bristol-Myers Squibb's Onglyza (saxagliptin), in the treatment of type 2 diabetes.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.